KZR

Kezar Life Sciences, Inc. [KZR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

KZR Stock Summary

Top KZR Correlated Resources

KZR

Top 10 Correlated ETFs

KZR

Top 10 Correlated Stocks

KZR

In the News

KZR Financial details

Company Rating
-
Market Cap
62.81M
Income
-99.91M
Revenue
7M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
58
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.79
Forward P/E
-
PEG
-0.19
P/S
9.45
P/B
0.31
P/C
-
P/FCF
-0.82
Quick Ratio
13.51
Current Ratio
13.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.38
EPS next Y
-
EPS next Q
-
EPS this Y
44.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
37.5%
-
-
-
-
SMA20
-20%
SMA50
-33.33%
SMA100
-42.86%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-35%
ROC
-0.42%
Gross Margin
100%
Oper. Margin
-1384%
Profit Margin
-1200%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.67-3.13
52W High
-
52W Low
-
RSI
46
Rel Volume
-
Avg Volume
750.67K
Volume
2.52K
Perf Week
-3.93%
Perf Month
-21.15%
Perf Quarter
-40.78%
Perf Half Y
-43.08%
-
-
-
-
Beta
0.481
-
-
Volatility
0.16%, 0.55%
Prev Close
0.23%
Price
4.4
Change
-1.23%

Something similar

Top by Market Cap
MIX.JO
VTSAX
EMBASSY.NS
VFINX
NVD.DE
Top Correlated ETFs
LABU
XBI
IBB
BIB
ZHP.TO
Top Correlated Stocks
TRDA
OVID
ANNX
CCCC
SOPA
Similar Market Cap
TRU.L
WINVU
UDA.TO
2078.HK
CTO.L

Company Profile

Healthcare Biotechnology
  • Volume Average 750.67K
  • Market Capitalization 62.81M
  • Employee 58
  • CEO Dr. Christopher J. Kirk Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2018-06-21
  • Website https://www.kezarlifesciences.com

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.